Linerixibat induced a dose-dependent reduction in itch among patients with primary biliary cholangitis-associated pruritus, according to results published in Clinical Gastroenterology and Hepatology.

The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked transformation over the past year, driven by the recent approvals ...

Linerixibat is an investigational inhibitor of the ileal bile acid transporter. The ongoing, global phase 3 GLISTEN study (ClinicalTrials.gov Identifier: ...

Linerixibat is an Ileal bile acid transporter inhibitor in Phase 2 clinical development for pruritus associated with adult cholestatic liver disease, primary biliary cholangitis (PBC).

Linerixibat, an ileal sodium-dependent bile acid transporter inhibitor, improved more than itch for patients with primary biliary cholangitis, despite a notable placebo effect, in the GLIMMER trial.

A regulatory filing seeking approval for linerixibat for the given indication is currently under review in the United States. A final decision from the FDA is expected on March 24, 2026.

Linerixibat is an IBAT inhibitor, a targeted oral agent with potential to treat cholestatic pruritus (itch) associated with the rare autoimmune liver disease known as PBC.

GSK’s linerixibat has shown promising results in a late-stage trial of primary biliary cholangitis (PBC) patients with cholestatic pruritus, or relentless itch. The phase 3 GLISTEN trial has been ...

British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat patients with a so-called relentless itch associated with a rare ...

(RTTNews) - GSK plc (GSK) announced the FDA has accepted for review the NDA for linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter, for the treatment of ...

Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC) · Primary endpoint met with a statistically significant improvement in ...

GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.